Table 1.

Studies showing the incidence and characteristics of neutropenia following alemtuzumab - based therapy in MS patients

Study	Treatment	No of patients	Incidence of neutropenia	Grade of neutropenia	Median time to neutropenia	Median duration of neutropenia	Treatment	Comments
Coles AJ et al., 2012 [16]	1rst year of infusion (24 mg/d)	1/161	0,60%	NA	NA	NA	NA	Febrile neutropenia
Willis et al, 2016 [9]	NA	1/100	1%	NA	Median time to development of acquired autoimmune manifestations was 995 days following first treatment.	NA	NA	None
Gaitán MI et al., 2017 [5]	1rst year of infusion (12 mg/d)	1	case report	IV	4 weeks	3 days	Granulocyte-stimulating factor (300 mg/day for 72 h)	Responsive to 1 cycle of G-SCF, but developed HSV-1 infection that needed advanced antibiotics
Gaitán MI et al., 2017 [5]	1rst year of infusion (12 mg/d)	1	case report	IV-III (two episodes)	6 and 8 weeks (two episodes)	3	Granulocyte-stimulating factor (300 mg/day for 72 h)	Responsive to 2 cycles of G-SCF. Febrile neutropenia andsinusitis that needed iv antibiotics
Baker D et al., 2017 [4]	1rst year of infusion (12 mg/d)	127/811	15,70%	I-II	NA	NA		Data from CARE-MS I and CARE-MS II.
Baker D et al., 2017 [4]	1rst year of infusion (12 mg/d)	5/811	0,60%	III-IV	NA	NA	2 patients developed agranulocytosis,the first teated with PLEX and the other with lenograstim	Data from CARE-MS I and CARE-MS II.
Baker D et al., 2017 [4]	2nd year of infusion	104/808	12,90%	I-II	NA	NA		Data from CARE-MS I and CARE-MS II.
Baker D et al., 2017 [4]	2nd year of infusion	12/808	1,50%	III-IV	NA	NA		Data from CARE-MS I and CARE-MS II.
Vakrakou. et al., 2018 [17]	1rst year of infusion (12 mg/d)	1	case report	III	9 weeks	9 days	Prezolon (25 mg for 3 days and 12,5 mg for another 3 days)	LGL cells predominated in peripheral blood
Galgani S et al., 2018 [6]	1rst year of infusion (12 mg/d)	1	Case report	III/IV	1 month	2 weeks	Resolved spontaneously